Copy Number Variation, Epithelial Ovarian Cancer, Genomic Structural Variation, Insertion-deletion Variation, Microsatellite Instability, Nucleotide Variant, PD-1, PD-L1, Total Mutation Burden
Conditions
Brief summary
Little is known about the characteristics of genetic mutation in a large multi-gene panel in epithelial ovarian cancer. This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than 500 hundred genes. The mutation characteristics are to be revealed in single nucleotide variants, copy number variations, insertion-deletion variations, and genomic structural variations. The total mutation burden (TMB) will be calculated. The status of microsatellite instability, expression of PD-1 and PD-L1 antibodies are also tested. These findings will be studies in association with the patients' prognosis and sensitivity to platinum-based chemotherapy.
Interventions
DIAGNOSTIC_TESTA multi-gene panel testing
A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
Sponsors
Lei Li
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 18 years or older * Pathology confirmed of recurrent cervical adenocarcinoma, squamous carcinoma or adenosquamous carcinoma * With available materials for analysis * With detailed clinicopathological information * Given consent to participate the trial
Exclusion criteria
* Not meeting all of the inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of genetic mutations | Two years | Frequency of various genetic mutations among recruited patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of microsatellite Instability | Two years | Microsatellite Instability in definite patient |
| Total mutation burden | Two years | Total mutation burden calculated in definite patient |
| Expression rates of PD-1 and PD-L1 antibodies | Two years | Expression rates of PD-1 and PD-L1 antibodies among recruited patients |
Countries
China
Contacts
Primary ContactLei Li, M.D.
Outcome results
None listed